Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)

Phase 1 Completed 24 enrolled Kinex Pharmaceuticals Inc.

NaSingle-groupOpen-labelTreatment

Summary

This Phase 1b study will determine the maximum tolerated dose of KX2-391 given as a once-daily dose, in elderly patients with acute myelogenous leukemia.

Timeline

Start: 2013-12
Primary completion: 2014-07
Completion: 2014-07

Publications

Kasner MT, Halloran MB, Pan J, Ritchie EK, Fetterly GJ, Kramer D, Hangauer DG, Thompson JE. A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia. Invest New Drugs. 2022 Aug;40(4):773-781. doi: 10.1007/s10637-022-01255-1. Epub 2022 May 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tirbanibulin	Small molecule	40 mg	Oral
Subject	Tirbanibulin	Small molecule	80 mg	Oral
Subject	Tirbanibulin	Small molecule	120 mg	Oral
Subject	Tirbanibulin	Small molecule	140 mg	Oral
Subject	Tirbanibulin	Small molecule	160 mg	Oral

Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)

Summary

Timeline

Publications

Drugs

Indications